Hemostemix Inc.
HEM.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.01% | 55.03% | 146.50% | 64.88% | 61.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.09% | 180.22% | 193.07% | 76.26% | 65.14% |
| Operating Income | -96.09% | -180.22% | -193.07% | -76.26% | -65.14% |
| Income Before Tax | -24.34% | -77.15% | -64.65% | -59.96% | -93.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.34% | -77.15% | -64.65% | -59.96% | -93.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.34% | -77.15% | -64.65% | -59.96% | -93.70% |
| EBIT | -96.09% | -180.22% | -193.07% | -76.26% | -65.14% |
| EBITDA | -96.08% | -180.22% | -193.10% | -76.28% | -65.17% |
| EPS Basic | 33.74% | -16.40% | -32.30% | -35.44% | -73.57% |
| Normalized Basic EPS | 4.61% | -51.69% | -29.37% | -10.74% | -46.15% |
| EPS Diluted | 33.74% | -16.40% | -32.30% | -35.44% | -73.57% |
| Normalized Diluted EPS | 4.61% | -51.69% | -29.37% | -10.74% | -46.15% |
| Average Basic Shares Outstanding | 73.68% | 59.32% | 40.76% | 25.19% | 10.41% |
| Average Diluted Shares Outstanding | 73.68% | 59.32% | 40.76% | 25.19% | 10.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |